FNY Partners Fund’s Array Biopharma Inc ARRY Stock Holding History

FNY Partners Fund’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,000	Closed	-$8K	–	772
2017 Q2	$8K	Buy	+1,000	New	+$8.18K	﹤0.01%	404

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FNY Partners Fund's ARRY Position: Q3 2017 in Review

FNY Partners Fund sold out of Array Biopharma Inc (ARRY) in Q3 2017, closing a stake of 1,000 shares — an estimated $8K sold.

FNY Partners Fund first reported a position in ARRY in Q2 2017 and held it in 1 quarter. The position peaked at $8K in Q2 2017. 184 funds tracked by Wall St. Rank hold ARRY as of Q3 2017.

FNY Partners Fund reported no remaining Array Biopharma Inc position as of Q3 2017 after selling out during the quarter.
FNY Partners Fund sold 1,000 Array Biopharma Inc shares in Q3 2017, an estimated $8K.
FNY Partners Fund first reported a position in Array Biopharma Inc in Q2 2017 and held it in 1 quarter.
FNY Partners Fund's Array Biopharma Inc position peaked at $8K in Q2 2017.
184 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2017.

Based on FNY Partners Fund's 13F filing for Q3 2017, filed 9 Nov 2017.